It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR).

[6] It can be characterized by the extracellular deposition of amyloids, foldable proteins that stick together to build fibrils in the heart.

[4] Electrocardiography can be used to identify low voltage and patterns similar to those of a heart attack.

[4] Acoramidis (Attruby) was approved for medical use in the United States in November 2024, to treat adults with cardiomyopathy of wild-type or variant (hereditary) transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.

[8][9] Outcomes for amyloid cardiomyopathy are generally very poor, with fewer than 10% of patients surviving more than 5 years.